SIGA Technologies, Inc. SIGA

Company Overview

SIGA Technologies, Inc. is a U.S.-based pharmaceutical company focused on the development and commercialization of therapeutics for health security and infectious diseases. The company operates primarily within the biodefense and antiviral pharmaceutical sectors, with a business model centered on supplying medical countermeasures to government agencies and preparedness programs. SIGA’s core commercial product is TPOXX (tecovirimat), an antiviral treatment approved in multiple jurisdictions for smallpox and related orthopoxvirus indications. Revenue has historically been heavily concentrated in procurement contracts with the U.S. government and international public health organizations.

The company was founded in 1995 and evolved from a broader biotechnology research platform into a specialized biodefense company following increased global focus on pandemic preparedness and national biosecurity initiatives. SIGA’s strategic positioning is tied to its regulatory approvals, intellectual property portfolio surrounding tecovirimat, and longstanding relationships with agencies such as the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA). The company has maintained a relatively focused operational structure compared with larger diversified pharmaceutical firms.